{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 448140837
| IUPAC_name = ''N''-(1-methyl-1,2-diphenylethyl)glycinamide
| image = Remacemide.svg
| width = 150px

<!--Clinical data-->
| tradename = Ecovia<ref name="FDA">{{cite web|title=Cumulative List of all Products that have received Orphan Designation|url=http://www.fda.gov/downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/UCM162066.xls.&ei=1rGaT8mBBsPe0QGwobWLDw&usg=AFQjCNEhWBsqoIwuoHkskBhX8qHLA_UB2g|publisher=FDA|accessdate=28 April 2012|author=FDA|format=excel document|date=2009-05-05}}</ref>
| routes_of_administration = oral

<!--Pharmacokinetic data-->
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 128298-28-2
| ATC_prefix = none
| PubChem = 60511
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = EH6763C1IC
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 54551
| smiles = CC(CC1=CC=CC=C1)(C2=CC=CC=C2)NC(=O)CN
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C17H20N2O/c1-17(19-16(20)13-18,15-10-6-3-7-11-15)12-14-8-4-2-5-9-14/h2-11H,12-13,18H2,1H3,(H,19,20)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = YSGASDXSLKIKOD-UHFFFAOYSA-N

<!--Chemical data-->
| C=17 | H=20 | N=2 | O=1 
| molecular_weight = 268.3535 g/mol
| synonyms = <small>(±)-2-amino-''N''-[1,2-di(phenyl)propan-2-yl]acetamide</small>
PR 934-423
}}
'''Remacemide''' is a [[pharmaceutical drug|drug]] which acts as a [[Ligand (biochemistry)#Receptor.2Fligand binding affinity|low-affinity]] [[NMDA antagonist]] with [[sodium]] [[ion channel|channel]] blocking properties.<ref name=Nachan>{{cite journal|last=Santangeli|first=Sarah|author2=Sills, Graeme J |author3=Thompson, George G |author4=Brodie, Martin J |title=Na+ channel effects of remacemide and desglycinyl-remacemide in rat cortical synaptosomes|journal=European Journal of Pharmacology|date=1 March 2002|volume=438|issue=1–2|pages=63–68|doi=10.1016/S0014-2999(02)01297-9}}</ref>  It has been studied for the treatment of acute [[ischemic stroke]],<ref>{{cite journal|last=MUIR|first=KEITH W.|author2=LEES, KENNEDY R. |title=Initial Experience with Remacemide Hydrochloride in Patients with Acute Ischemic Stroke|journal=Annals of the New York Academy of Sciences|date=1 September 1995|volume=765|issue=1 Neuroprotecti|pages=322–323|doi=10.1111/j.1749-6632.1995.tb16602.x}}</ref><ref>{{cite journal|last1=Dyker|first1=AG|last2=Lees|first2=KR|title=Remacemide Hydrochloride: A Double-Blind, Placebo-Controlled, Safety and Tolerability Study in Patients With Acute Ischemic Stroke|journal=Stroke|year=1999|volume=30|pages=1796–1801|pmid=10471426|issue=9|doi=10.1161/01.STR.30.9.1796}}</ref> [[epilepsy]],<ref>{{cite journal|pmid=19111629|year=2009|last1=Wesnes|first1=KA|last2=Edgar|first2=C|last3=Dean|first3=AD|last4=Wroe|first4=SJ|title=The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy|volume=14|issue=3|pages=522–8|doi=10.1016/j.yebeh.2008.11.012|journal=Epilepsy & behavior : E&B}}</ref> [[Huntington's disease]], and [[Parkinson's disease]].

Because remacemide has only a modest effect on seizure frequency and causes [[dizziness]], it is no longer believed that remacemide will be an effective treatment for epilepsy.<ref name ="Leach">{{cite journal|last=Leach|first=JP |author2=Marson, AG |author3=Hutton, JL|title=Remacemide for drug-resistant localization related epilepsy.|journal=Cochrane database of systematic reviews (Online)|year=2002|issue=4|pages=CD001900|pmid=12519561|doi=10.1002/14651858.CD001900}}</ref> Although no such statement has been made about remacemide's potential for treating stroke, Huntington's, or Parkinson's, remacemide is no longer being developed for these conditions.<ref>{{cite web|title=Development Pipeline as at 31 December 2011|url=http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3DR%26amp%3BD-pipeline-table.pdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285632489300&ssbinary=true|publisher=AstraZeneca|accessdate=15 May 2012}}</ref>

Remacemide is also known as remacemide hydrochloride, (±)-2-amino-''N''-(1-methyl-1,2-diphenylethyl)-acetamide hydrochloride, or FPL 12924AA.<ref name ="bio">{{cite journal|last=Palmer|first=GC |author2=Murray, RJ |author3=Wilson, TC |author4=Eisman, MS |author5=Ray, RK |author6=Griffith, RC |author7=Napier, JJ |author8=Fedorchuk, M |author9=Stagnitto, ML |author10=Garske, GE|title=Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide.|journal=Epilepsy research|date=June 1992|volume=12|issue=1|pages=9–20|pmid=1388119|doi=10.1016/0920-1211(92)90086-9}}</ref>
{{TOC limit|3}}

==Adverse effects==
*dizziness<ref name = "Leach"/><ref name=RAMP>{{cite journal|last=Parkinson Study Group|title=A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD.|journal=Neurology|date=2000-04-25|volume=54|issue=8|pages=1583–8|pmid=10762497|doi=10.1212/wnl.54.8.1583}}</ref>
*nausea<ref name= RAMP/>

===Lack of adverse effects===
Unlike many other treatments for epilepsy, remacemide does not appear to impair cognitive performance<ref>{{cite journal|last=Lockton|first=JA|author2=Cole G |author3=Hammersley M |author4=Wesnes K |title=Cognitive function is unaffected by remacemide at therapeutic relevant single doses|journal=J Psychopharmacol|year=1998|volume=12|issue=A41}}</ref><ref>{{cite journal|last=Lockton|first=JA|author2=Wesnes KA |author3=Yeates N |author4=Rolan O |author5=Diggory G |title=Remacemide does not affect cognitive function following multiple dosing|journal=J Psychopharmacol|year=1998|volume=12|issue=A41}}</ref><ref>{{cite journal|last=Wesnes|first=K.A.|author2=Edgar, C. |author3=Dean, A.D.P. |author4=Wroe, S.J. |title=The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy|journal=Epilepsy & Behavior|date=1 March 2009|volume=14|issue=3|pages=522–528|doi=10.1016/j.yebeh.2008.11.012|pmid=19111629}}</ref> or driving performance<ref>{{cite journal|first=J.|last=Ramaekers |author2=C. Lamers |author3=F. Verhey |author4=N. Muntjewerff |author5=E. Mobbs |author6=N. Sanders |author7=J. Lewis |author8=J. Lockton |title=A comparative study of the effects of carbamazepine and the NMDA receptor antagonist remacemide on road tracking and car-following performance in actual traffic|journal=Psychopharmacology|date=1 January 2002|volume=159|issue=2|pages=203–210|doi=10.1007/s002130100898 |pmid=11862350}}</ref> in humans, although the evidence for effects on cognitive performance in animals has been mixed.<ref>{{cite journal|last1=Wright|first1=LK|last2=Pearson|first2=EC|last3=Hammond|first3=TG|last4=Paule|first4=MG|title=Behavioral effects associated with chronic ketamine or remacemide exposure in rats|journal=Neurotoxicol Teratol|date=May–Jun 2007|volume=29|issue=3|pages=348–59|doi=10.1016/j.ntt.2006.12.004|pmid=17291718}}</ref><ref>{{cite journal|last=Popke|first=E.J|author2=Allen, R.R |author3=Pearson, E.C |author4=Hammond, T.G |author5=Paule, M.G |title=Differential effects of two NMDA receptor antagonists on cognitive–behavioral development in nonhuman primates I|journal=Neurotoxicology and Teratology|date=1 July 2001|volume=23|issue=4|pages=319–332|doi=10.1016/S0892-0362(01)00156-8}}</ref><ref>{{cite journal|last=Popke|first=E.J|author2=Allen, R.R |author3=Pearson, E.C |author4=Hammond, T.G |author5=Paule, M.G |title=Differential effects of two NMDA receptor antagonists on cognitive–behavioral performance in young nonhuman primates II|journal=Neurotoxicology and Teratology|date=1 July 2001|volume=23|issue=4|pages=333–347|doi=10.1016/S0892-0362(01)00138-6}}</ref><ref>{{cite journal|last=Popke|first=E.J|author2=Patton, R |author3=Newport, G.D |author4=Rushing, L.G |author5=Fogle, C.M |author6=Allen, R.R |author7=Pearson, E.C |author8=Hammond, T.G |author9=Paule, M.G  |title=Assessing the potential toxicity of MK-801 and remacemide:|journal=Neurotoxicology and Teratology|date=1 March 2002|volume=24|issue=2|pages=193–207|doi=10.1016/S0892-0362(02)00206-4}}</ref><ref>{{cite journal|last=PAULE|first=MERLE G.|author2=FOGLE, C. MATTHEW |author3=ALLEN, RICHARD R. |author4=PEARSON, EDWIN C. |author5=HAMMOND, TIMOTHY G. |author6=POPKE, E. JON |title=Chronic Exposure to NMDA Receptor and Sodium Channel Blockers during Development in Monkeys and Rats|journal=Annals of the New York Academy of Sciences|date=1 May 2003|volume=993|issue=1|pages=116–122|doi=10.1111/j.1749-6632.2003.tb07519.x}}</ref> 
Remacemide is not a sedative.<ref name =preclinmice/>

==Toxicity==
The [[median toxic dose]] of remacemide for neural impairment tests in mice is 5.6&nbsp;mg/kg.<ref name =preclinmice/>
Its estimated [[median lethal dose]] is about 927.3&nbsp;mg/kg in mice.<ref name =preclinmice/>
It has a favorable [[therapeutic index]] of 28.1 in mice.<ref name =preclinmice/>

==Drug interactions==

===Levodopa===
Remacemide delays the absorption of [[L-DOPA|levodopa]] (300&nbsp;mg of remacemide one hour before levodopa treatment delays mean time to peak levodopa plasma concentration by 20%) but not its total absorption (area-under-the-curve for levodopa plasma concentration was unchanged).<ref name = "SPIRAL">{{cite journal|last=The Parkinson Study Group|title=The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease. Parkinson Study Group.|journal=Clin Neuropharmacol|date=Jul–Aug 1999|volume=22|issue=4|pages=220–5|pmid=10442252}}</ref>

===Sodium valproate===
Remacemide does not interact with [[sodium valproate]], a treatment for epilepsy.<ref>{{cite journal|last=Leach|first=J.P.|author2=Girvan, J. |author3=Jamieson, V. |author4=Jones, T. |author5=Richens, A. |author6=Brodie, M.J. |title=Lack of pharmacokinetic interaction between remacemide hydrochloride and sodium valproate in epileptic patients|journal=Seizure|date=1 June 1997|volume=6|issue=3|pages=179–184|doi=10.1016/S1059-1311(97)80003-9}}</ref>

===Carbamazepine===
Ramacemide does interact with [[carbamazepine]].  Remacemide inhibits the metabolism of carbamazepine, while carbamazepine induces the metabolism of remacemide and FPL 12495.<ref>{{cite journal|last=Leach|first=John Paul |author2=Blacklaw, Jackie |author3=Jamieson, Virginia |author4=Jones, Tracey |author5=Richens, Alan |author6=Brodie, Martin J. |title=Mutual Interaction Between Remacemide Hydrochloride and Carbamazepine: Two Drugs with Active Metabolites|journal=Epilepsia|date=1 November 1996|volume=37|issue=11|pages=1100–1106|doi=10.1111/j.1528-1157.1996.tb01031.x}}</ref>

===Alcohol===

==Remacemide salts==
Remacemide is most commonly synthesized as the [[salt (chemistry)|salt]] remacemide hydrochloride.  However, there has been some investigation into other remacemide salts and their [[crystal]]s, as different remacemide salts might taste more pleasant or have a [[solubility]] more suitable for a pediatric [[suspension (chemistry)|suspension]] [[Pharmaceutical formulation|formulation]].<ref>{{cite journal|last=Lewis|first=Gareth R. |author2=Steele, Gerry |author3=McBride, Lorraine |author4=Florence, Alastair J. |author5=Kennedy, Alan R. |author6=Shankland, Norman |author7=David, William I. F. |author8=Shankland, Kenneth |author9=Teat, Simon J. |title=Hydrophobic vs. Hydrophilic:  Ionic Competition in Remacemide Salt Structures|journal=Crystal Growth & Design|date=1 March 2005|volume=5|issue=2|pages=427–438|doi=10.1021/cg049836u}}</ref>

==Mechanism of action==
Remacemide binds weakly and [[Noncompetitive antagonist#Non-competitive|noncompetitively]] to the ionic channel site of the [[NMDA receptor|NMDA receptor complex]].<ref name = "bio"/> Remacemide binds both allosterically and in the channel.<ref name=NMDARaction>{{cite journal|last=Subramaniam|first=S |author2=Donevan, SD |author3=Rogawski, MA|title=Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite.|journal=The Journal of Pharmacology and Experimental Therapeutics|date=January 1996|volume=276|issue=1|pages=161–8|pmid=8558426}}</ref> 
However, because remacemide binds so weakly to NMDAR, much of remacemide's ''in vivo'' effect against [[excitotoxicity]] is thought to be caused by its metabolic transformation to the more potent desglycine derivative [[Remacemide#FP 12495|FPL 12495]].<ref name = "bio"/>  That is, remacemide may actually act as a [[prodrug]] to deliver the active [[metabolite]] FPL 12495 to the central nervous system.<ref name = brainup>{{cite journal|last=Heyn|first=H |author2=McCarthy, DJ |author3=Curry, SH |author4=Eisman, MS |author5=Anders, MW|title=Brain uptake and biotransformation of remacemide hydrochloride, a novel anticonvulsant.|journal=Drug metabolism and disposition: the biological fate of chemicals|date=May–Jun 1994|volume=22|issue=3|pages=443–6|pmid=8070322}}</ref>

===Epilepsy===
In a well validated and described genetic model of absence epilepsy, rats of the WAG/Rij strain, remacemide and its metabolite FPL 12495 were found to have a common for glutamate antagonist usual effect on the number of spike/wave discharges[[Electroencephalography|EEG]], the drugs decrease spike/wave dischanges dose dependently. However, in contrast to most other glutamate antagonists, FPL 12495 increased the duration of the spike-wave discharges.<ref>{{cite journal|last=Van Luijtelaar|first=E.L.J.M.|author2=Coenen, A.M.L. |title=Effects of remacemide and its metabolite FPL 12495 on spike-wave discharges, electroencephalogram and behaviour in rats with absence epilepsy|journal=Neuropharmacology|date=1 April 1995|volume=34|issue=4|pages=419–425|doi=10.1016/0028-3908(95)00008-T}}</ref>

==Pharmacokinetics==

===Blood–brain barrier===
The brain uptake index (BUI), a measure of a drug's ability to pass the [[blood–brain barrier]] that involves the injection of [[Isotopic labeling#Radioisotopic labeling|radiolabeled]] test and reference substances into the [[common carotid artery]] of anesthetized animals,<ref>{{cite journal|last=Hardebo|first=JE|author2=Nilsson, B |title=Estimation of cerebral extraction of circulating compounds by the brain uptake index method: influence of circulation time, volume injection, and cerebral blood flow.|journal=Acta physiologica Scandinavica|date=October 1979|volume=107|issue=2|pages=153–9|pmid=525379|doi=10.1111/j.1748-1716.1979.tb06455.x}}</ref><ref>{{cite journal|last=Oldendorf|first=WH |author2=Pardridge, WM |author3=Braun, LD |author4=Crane, PD|title=Measurement of cerebral glucose utilization using washout after carotid injection in the rat.|journal=Journal of Neurochemistry|date=May 1982|volume=38|issue=5|pages=1413–8|pmid=7062059|doi=10.1111/j.1471-4159.1982.tb07920.x}}</ref> for remacemide is 51 ± 0.9 SD.<ref name = brainup/>

==Enantiomers==
The [[Chirality (chemistry)#By optical activity: (+)- and (−)- or d- and l-|(-)]][[Stereoisomerism|stereoisomer]] of remacemide is of equal potency to the racemic mixture in preventing maximal electroshock seizures when administered orally to rats, while the (+)stereoisomer is less potent.<ref name= ent/>

==Metabolites==

===FPL 12495===
Much of remacemide's effect ''in vivo'' is thought to be caused by the desglycine derivative FPL 12495 [[Racemic mixture#Nomenclature|(±)]].<ref name = "bio"/>
FPL 12495 (±) binds specifically and non-competitively to NMDAR,.<ref>{{cite journal|last=Hu|first=Ruo Qi|author2=Davies, John A. |title=The effect of the desglycinyl metabolite of remacemide on cortical wedges prepared from DBA/2 mice|journal=European Journal of Pharmacology|date=1 December 1995|volume=287|issue=3|pages=251–256|doi=10.1016/0014-2999(95)00500-5}}</ref>  Its effect on maximal electroconvulsive shock is more [[Potency (pharmacology)|potent]] than remacemide.<ref name = "bio"/>  The [[Chirality (chemistry)#By configuration: R- and S-|S isomer]] (FPL 12859) is even more potent than the [[racemic mixture]], while the R isomer is less potent than the racemate.<ref name = "bio"/>

FPL 12495 is sometimes referred to as ARL 12495AA.<ref>{{cite journal|last=Norris|first=S.K.|author2=King, A.E. |title=Electrophysiological effects of the anticonvulsant remacemide hydrochloride and its metabolite ARL 12495AA on rat CA1 hippocampal neurons in vitro|journal=Neuropharmacology|date=1 July 1997|volume=36|issue=7|pages=951–959|doi=10.1016/S0028-3908(97)00069-5}}</ref><ref>{{cite journal|last=Leach|first=JP |author2=Sills, GJ |author3=Butler, E |author4=Forrest, G |author5=Thompson, GG |author6=Brodie, MJ|title=Neurochemical actions of the desglycinyl metabolite of remacemide hydrochloride (ARL 12495AA) in mouse brain.|journal=British Journal of Pharmacology|date=July 1997|volume=121|issue=5|pages=923–6|pmid=9222548|doi=10.1038/sj.bjp.0701219|pmc=1564774}}</ref><ref>{{cite journal|last=Norris|first=SK|author2=King, AE |title=The stereo-isomers of the anticonvulsant ARL 12495AA limit sustained repetitive firing and modify action potential properties of rat hippocampal neurons in vitro.|journal=The Journal of Pharmacology and Experimental Therapeutics|date=June 1997|volume=281|issue=3|pages=1191–8|pmid=9190853}}</ref>

===Other metabolites===

====FPL 15053====
FPL 15053 is the ''N''-hydroxy-desglycinate of remacemide, and exhibits modest binding to NMDAR and modest effects on convulsions and mortality in test mice and rats.<ref name = "bio"/>

====FPL 14331 and FPL 14465====
FPL 14331 and FPL 14465 are the ''p''-hydroxy-desglycinates of remacemide, and they exhibit some efficacy against maximal electroconvulsive shock after i.p. and i.v. dosing.<ref name = "bio"/>

====FPL 15455====
FPL 15455 is an oxoacetate matabolite of remacemide, but has no demonstrated biological activity.<ref name = "bio"/>

====FPL 14991 and FPL 14981====
FPL 14991 and FPL 14981 are both ''β''-Miydroxy-desglycinates of remacemide, and they display modest efficacy against maximal electroconvulsive shock in mice.<ref name = "bio"/>  However FPL 14981 and not FPL 14991 prevents NMDLA-induced convulsions and mortality in mice.<ref name = "bio"/>

====FPL 13592 and FPL 15112====
The hydroxy-methyl derivative of remacemide (FPL 13592) and its desglycinate (FPL 15112) prevents electric shock-induced convulsions only after i.v. administration; only the desglycine derivative binds to NMDAR.<ref name = "bio"/>

====FPL 14467====
FPL 14467 (''p''-dihydroxy-desglycine) is inactive ''in vivo'' and weak in binding NMDAR.<ref name = "bio"/>

==Pharmacodynamics==
The [[IC50|values for 50% displacement]] of [[MK801|[<sup>3</sup>H]MK801]] were 68 µM for remacemide and 0.48 µM for  FPL 12495AA.<ref name ="bio"/>

==History==

===Current status===
Remacemide is an [[experimental drug]] most recently being developed by the British multinational [[pharmaceutical industry|pharmaceutical company]] [[AstraZeneca]].  However, there has been little news of its progress since 2000.  A few sources indicate that its development has been discontinued.<ref>{{cite web|title=remacemide () UKMi New Drugs Online Database|url=http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=2781|accessdate=2 May 2012}}</ref><ref name ="dis">{{cite news|title=remacemide AstraZeneca discontinued, Europe, USA, Canada (epilepsy)|url=http://business.highbeam.com/436989/article-1G1-114382356/remacemide-astrazeneca-discontinued-europe-usa-canada|accessdate=2 May 2012|newspaper=R & D Focus Drug News|date=March 15, 2004}}</ref>

===Changing hands===
Remacemide was one of the last drugs under development by the now-defunct English pharmaceutical company [[Fisons]].<ref name="fisons">{{cite news|title=FISONS DISCONTINUES TIPREDANE DEV'T|url=http://www.thepharmaletter.com/file/34535/fisons-discontinues-tipredane-devt.html|accessdate=28 April 2012|newspaper=the pharma letter|date=12 April 1993}}</ref>  In 1995, it was acquired along with most of Fisons' [[research and development]] operations by the Swedish pharmaceutical company [[Astra AB|Astra]],<ref name="astra">{{cite news|title=Sweden's Astra Buys Most Of Fisons R&D Ops|url=http://www.thepharmaletter.com/file/40335/swedens-astra-buys-most-of-fisons-rd-ops.html|accessdate=28 April 2012|newspaper=the pharma letter|date=27 March 1995}}</ref> which in 1999 merged with the British company [[Zeneca]] to form [[AstraZeneca]].<ref>{{cite web|title=AstraZeneca History|url=http://www.astrazeneca.com/About-Us/History|publisher=AstraZeneca|accessdate=29 April 2012}}</ref>  In 2000, AstraZeneca considered possibly licensing out remacemide to some other pharmaceutical company,<ref name = "lic">{{cite web|title=AstraZeneca R&D Pipeline: NCEs|url=http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3DR%26amp%3BD-Pipeline-table.pdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285616469893&ssbinary=true|publisher=AstraZeneca|accessdate=28 April 2012|year=2000}}</ref> but there has been little news about remacemide since then.  Remacemide's development may have been discontinued in July 2001.<ref name = "dis"/>

====Discovery and development under Fisons====
In 1990, researchers at Fisons found that remacemide acted as an [[anticonvulsant]] in mice and rats<ref name=preclinmice>{{cite journal|last=Stagnitto|first=ML |author2=Palmer, GC |author3=Ordy, JM |author4=Griffith, RC |author5=Napier, JJ |author6=Becker, CN |author7=Gentile, RJ |author8=Garske, GE |author9=Frankenheim, JM |author10=Woodhead, JH|title=Preclinical profile of remacemide: a novel anticonvulsant effective against maximal electroshock seizures in mice.|journal=Epilepsy research|date=Sep–Oct 1990|volume=7|issue=1|pages=11–28|pmid=1963406|doi=10.1016/0920-1211(90)90050-6}}</ref><ref name= ent>{{cite journal|last=Garske|first=GE |author2=Palmer, GC |author3=Napier, JJ |author4=Griffith, RC |author5=Freedman, LR |author6=Harris, EW |author7=Ray, R |author8=McCreedy, SA |author9=Blosser, JC |author10=Woodhead, JH|title=Preclinical profile of the anticonvulsant remacemide and its enantiomers in the rat.|journal=Epilepsy research|date=September 1991|volume=9|issue=3|pages=161–74|pmid=1660399|doi=10.1016/0920-1211(91)90050-p}}</ref> 
.<ref>{{cite journal|last=Palmer|first=GC |author2=Harris, EW |author3=Napier, JJ |author4=Stagnitto, ML |author5=Garske, GE |author6=Griffith, RC |author7=Swinyard, EA|title=Status of PR 934-423, a novel anticonvulsant targeted for generalized tonic/clonic seizures (new designation is FPL 12924AA).|journal=Progress in clinical and biological research|year=1990|volume=361|pages=435–41|pmid=2290849}}</ref>  Because of remacemide's potential as a [[neuroprotection|neuroprotective]] agent through preventing [[excitotoxicity|glutamate toxicity]], it was soon also under investigation as a [[NMDA receptor antagonist#Potential for treatment of excitotoxicity|treatment]] for [[Huntington's disease]]<ref name = "Hunt">{{cite journal|last=Kieburtz|first=Karl |author2=Feigin, Andrew |author3=McDermott, Michael |author4=Como, Peter |author5=Abwender, David |author6=Zimmerman, Carol |author7=Hickey, Charlyne |author8=Orme, Constance |author9=Claude, Kathy |author10=Sotack, Jennie |author11=Greenamyre, J. Timothy |author12=Dunn, Cynthia |author13=Shoulson, Ira |title=A controlled trial of remacemide hydrochloride in Huntington's disease|journal=Movement Disorders|date=1 May 1996|volume=11|issue=3|pages=273–277|doi=10.1002/mds.870110310}}</ref> and [[Parkinson's disease]].<ref>{{cite journal|last=Greenamyre|first=JT |author2=Eller, RV |author3=Zhang, Z |author4=Ovadia, A |author5=Kurlan, R |author6=Gash, DM|title=Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.|journal=Annals of Neurology|date=June 1994|volume=35|issue=6|pages=655–61|pmid=8210221|doi=10.1002/ana.410350605}}</ref>

====Astra====
By 1995, when [[Astra AB|Astra]] acquired remacemide, it was already in [[Phases of clinical research#Phase II|Phase IIb]] clinical development as an anti-epileptic drug<ref name="astra" /> and [[Phases of clinical research#Phase I|Phase I]] clinical development as a treatment for Huntington's
.<ref name = "Hunt"/><ref>{{cite web|title=Completed Clinical Trials|url=http://www.huntington-study-group.org/ClinicalResearch/CompletedClinicalTrials/tabid/65/Default.aspx|publisher=Huntington Study Group|accessdate=29 April 2012|year=2010}}</ref>

====AstraZeneca====
By 1998, when Astra announced its merger with [[Zeneca]], remacemide had progressed to [[Phases of clinical research#Phase III|Phase III]] trials for epilepsy and [[Phases of clinical research#Phase II|Phase II]] trials for Parkinson's disease, and Astra was also investigating its potential for treating [[neuropathic pain]]<ref>{{cite web|title=Astra 98 Annual Report|url=http://reports.huginonline.com/hugin/756071.pdf|publisher=Stellan Ståls Grafiska AB|accessdate=28 April 2012}}</ref>

In 1999, after the merger, AstraZeneca reported that they were investigating remacemide for its [[neuroprotection|neuroprotective]] effects, and that they planned regulatory submissions for [[Huntington's Disease]] in 2001 and for [[Parkinson's disease]] and [[epilepsy]] in 2003.<ref>{{cite web|last=Polinsky|first=Ron|title=AstraZeneca CNS|url=http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3DCNS---Ron-Polinsky.pdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285616440467&ssbinary=true|publisher=AstraZeneca|accessdate=27 April 2012}}</ref>

Remacemide, under the trade name Ecovia, was designated an [[orphan drug]] for the treatment of [[Huntington's Disease]] by the [[Food and Drug Administration|FDA]] in March 2000.<ref name="FDA"/>

Remacemide was last mentioned in [[AstraZeneca]]'s reports on its [[Research and Development|R&D]] pipeline in 2000, when it was in [[Phases of clinical research#Phase III|Phase III]] [[clinical trial]]s for remacemide in the treatment of [[Huntington's disease]] and [[Phases of clinical research#Phase II|Phase II]] for treatment of [[Parkinson's disease]].  At that time, the submission of the [[New Drug Application|New Drug Application (NDA)]] to the [[Food and Drug Administration|FDA]] and the [[Marketing Authorization Application]] to the [[Committee for Medicinal Products for Human Use|CHMP]] was projected for Huntington's in 2001 and for Parkinson's after 2003,<ref name = "lic"/> but there has been no news of such submission.  In this report, it was also noted that remacemide was "under strategic review and a potential candidate for licensing activity"<ref name = "lic"/> (see this [http://pharmalicensing.com/public/articles/view/1053089151_3ec4dd7f9a2e3/big-pharma-licensing-strategies external article] about drug [[license|licensing]].)

====Current news====
There are no clinical trials of remacemide in progress, according to the Huntington Study Group,<ref>{{cite web|title=Clinical Trials and Observational Studies in Progress|url=http://www.huntington-study-group.org/ClinicalResearch/ClinicalTrialsObservationalStudiesinProgress/tabid/81/Default.aspx|publisher=Huntington Study Group|accessdate=29 April 2012|year=2010}}</ref> and the Parkinson Study Group.<ref>{{cite web|title=Clinical Trials in Progress - Parkinson Study Group|url=http://www.parkinson-study-group.org/parkinson-research/clinical-trials-in-progess/|accessdate=2 May 2012}}</ref>

==Availability==
Remacemide is an [[experimental drug]] not available to the public and not currently undergoing [[clinical trials]].  It is available for research purposes from Tocris Bioscience, under license from [[AstraZeneca]].<ref>{{cite web|title=Remacemide hydrochloride Cat. No. 1622|url=http://www.tocris.com/dispprod.php?ItemId=56447|publisher=Tocris|accessdate=29 April 2012}}</ref>

==See also==
* [[AD-1211]]
* [[Diphenidine]]
* [[Ephenidine]]
* [[Lanicemine]]
* [[Lefetamine]]
* [[Methoxphenidine]] (MXP)
* [[MT-45]]

== References ==
{{Reflist}}

==External links==
* [http://www.stanford.edu/group/hopes/cgi-bin/wordpress/2010/06/remacemide/ Huntington's Outreach Project for Education, at Stanford]

{{Hallucinogens}}
{{Ion channel modulators}}
{{Ionotropic glutamate receptor modulators}}

[[Category:Acetamides]]
[[Category:Amino acid derivatives]]
[[Category:Dissociative drugs]]
[[Category:NMDA receptor antagonists]]
[[Category:Diarylethylamines]]
[[Category:Sodium channel blockers]]